Apogee Therapeutics, Inc. announced two abstracts co-written with Apogee?s research partner, Paragon Therapeutics, Inc., highlighting the company?s lead product candidate, APG777, a fully optimized and half-life extended antibody targeting IL-13 for the treatment of AD, have been accepted as e-posters at the upcoming 2023 European Academy of Dermatology and Venereology (EADV) Congress, held October 11-14, 2023, in Berlin, Germany and virtually.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
41.14 USD | -4.59% | -1.32% | +47.24% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.24% | 2.4B | |
+40.80% | 53.67B | |
+35.79% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |
- Stock Market
- Equities
- APGE Stock
- News Apogee Therapeutics, Inc.
- Apogee Therapeutics, Inc. and Paragon Therapeutics, Inc. Announce Two Abstracts Accepted for Presentation at the 2023 European Academy of Dermatology and Venereology Congress